Synermore is a Taiwan based biotech company focused on the research and development of innovative and biosimilar monoclonal antibodies in the areas of oncology, infectious diseases, and immune disorders. The core competence is to bring products from research stage through IND-enabling nonclinical and CMC activities to clinical stage of development.
Pursuing global development of our products, Synermore has filed several INDs in both the US and China. The first human clinical trial of our lead product has initiated in 1Q2015 in the US. Synermore has a Process Development group in Beijing, a GMP manufacturing facility in Shenzhen, and preclinical development and clinical operations in Taipei.
Over the years, the company has established a large number of the state-of-the-art technologies and platforms necessary for development and production of therapeutic monoclonal antibodies. These include preparation and screening of hybridomas, antibody engineering and humanization, cell line construction and screening, CHO cell based culture platforms for high-density antibody expression, fermentation and purification, advanced analytical technologies for antibody characterization, and antibody drug formulation.